Think Positive: Clovis Confident Of CHMP Okay For Rubraca
Executive Summary
The US biotech expects to finally get its PARP inhibitor for ovarian cancer onto the European market in the next few months to compete with rivals AstraZeneca and Tesaro after the CHMP "communicated a positive trend vote" ahead of an opinion being issued next month.
You may also be interested in...
Fresh EU Okay For Rubraca Boosts Clovis
Rumors that Clovis is going to be an M&A target soon are on the rise after a second thumbs-up in Europe for the firm's PARP inhibitor Rubraca, this time as maintenance therapy for platinum-sensitive ovarian cancer in all-comers.
Clovis Confident, Portola Not: CHMP Decides On EU Marketing Applications
Eight EU marketing authorization applications are up for an opinion this week from the CHMP, the European Medicines Agency committee that recommends whether or not products should be approved.
Bumper Number Of 'Oral Explanations' Due At CHMP Meeting
An unusually large number of companies are due to appear this week before the European Medicines Agency’s key advisory panel, the CHMP, to answer questions about initial marketing authorization applications or indication extension requests. The CHMP has questions regarding nine different products.